We're moving to rndsystems.com. Come with us!

After August 17, 2026, Novus Biologicals products and services will no longer be available on this website; you will access all products and services on rndsystems.com. Create your R&D Systems online account today.

Immunotherapy

NPC1: A Potential Target For Triple-Negative Breast Cancer

Hypoxia-Dependent CAR Stabilizing Construct in T cells Improves Solid Tumor Targeting and Efficacy

Synthetic Biotic Medicine as Immunotherapy Against Cancer: Evidence From Arginine-Producing Engineered Bacteria

Harnessing Natural Killer Cell Activity for Anti-Tumor Immunotherapy

Success of combined IL-10 and IL-12 therapy in colon cancer depends on IFN-gamma and gut barrier integrity

Advancing CAR T Therapies with CRISPR/Cas9

Adenosine Inhibits T cell Tumor Infiltration: KCa3.1, a New Anticancer Target